文献速递消化道肿瘤与早癌消化内镜

贝伐珠单抗治疗患者恶性结肠梗阻金属支架的安全性与有效性

Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab.
PubMed 文献 · Gastrointest Endosc · 2019-02-21

研究纳入2007至2016年本院接受自膨式金属支架(SEMS)治疗恶性结肠梗阻(MCO)的199例患者,技术成功率99.5%、临床成功率89%,46例发生48次不良事件(24%);贝伐珠单抗组与非贝伐珠单抗组穿孔率无显著差异(P=0.549),但需更大样本进一步验证。

要点

  • SEMS治疗MCO技术成功率高(99.5%),临床成功率欠佳(89%)。
  • 弯曲段狭窄及外压性压迫与临床成功率低相关。
  • 贝伐珠单抗组与非贝伐珠单抗组穿孔率无显著差异(P=0.549)。

核心结论

  • SEMS治疗MCO技术成功率高但临床成功率欠佳,弯曲段狭窄和外压性压迫与不良结局相关,贝伐珠单抗组穿孔率未高于非贝伐珠单抗组,但需更大样本进一步验证。

研究设计与样本

  • 单中心研究,纳入2007至2016年本院接受SEMS治疗MCO的患者199例,平均年龄58岁,54%为男性,99%为IV期癌症。

主要发现

  • 技术成功率为99.5%,临床成功率为89%。
  • 46例患者发生48次不良事件(24%),其中2%为围手术期、15%为术后、83%发生于72小时后。
  • 支架相关不良事件25例,包括持续梗阻14例、闭塞10例、膨胀失败1例。
  • 操作相关不良事件23例,包括轻微出血2例、穿孔4例、腹痛12例、支架移位4例、呼吸功能不全1例。
  • 104例接受贝伐珠单抗治疗者中22%发生不良事件,包括1例穿孔,非贝伐珠单抗组穿孔3例(P=0.549)。

关键数值与推荐

  • 临床成功定义为术后可成功经口进食,技术成功定义为支架在预定位置跨越狭窄段释放。
  • MCO病因:结直肠癌82%,外压性压迫17%。
  • 支架置入部位:左半结肠90%,横结肠4.5%,升结肠5.5%;弯曲段30%,直段70%。
  • 27例需要串联支架;46例中21例进行了重复操作。
  • SEMS后48例接受手术,包括切除加一期吻合8例、切除加永久性造口18例、未切除的转流性造口19例;SEMS置入至手术平均时间175天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 贝伐珠单抗组穿孔率虽未高于非贝伐珠单抗组,但需在更大样本中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The aim of this study was to examine clinical outcomes and adverse events (AEs) of self-expandable metal stents (SEMSs) in the management of malignant colonic obstruction (MCO). METHODS: Patients with SEMSs for MCO treated at our institution from 2007 to 2016 were included. Clinical success was defined as successful oral intake after the procedure and technical success as stent deployment across the stricture in the desired location. RESULTS: Of 199 patients, the mean age was 58, 54% were men, and 99% had stage IV cancer. MCO etiology was colorectal cancer in 82% and extrinsic compression in 17%. Technical success was achieved in 99.5% and clinical success in 89%. The SEMSs were palliative in 97% and were a bridge to surgery in 4%. MCO occurred in the left side of the colon in 90%, transverse in 4.5%, and ascending colon in 5.5%. SEMSs were placed in curved segments in 30% and straight segments in 70%. Tandem SEMSs were required in 27 patients. Forty-six patients had 48 AEs (24%), including 2% periprocedure, 15% postprocedure, and 83% after 72 hours. Stent-related AEs (n = 25) included persistent obstruction (n = 14), occlusion (n = 10), and failure of expansion (n = 1). Procedural AEs (n = 23) included minor bleeding (n = 2), perforations (n = 4), abdominal pain (n = 12), stent migration (n = 4), and respiratory insufficiency (n = 1). Repeat procedures were performed in 21 of 46 patients. After SEMSs, 48 patients underwent surgery, including resection with primary anastomosis (n = 8), resection with definitive stoma (n = 18), and diverting stoma without resection (n = 19). Mean time to surgery after SEMS placement was 175 days. Postsurgical AEs occurred in those with resections (leak, 2; infection, 2). Of 104 receiving bevacizumab, 22% had AEs, including 1 perforation compared with 3 in the nonbevacizumab group (P = .549). Mean overall survival was 5.6 months. Extrinsic compression and curved strictures were associated with poor clinical success by univariate analysis and etiology (noncolonic with poor outcome) by multivariate analysis. CONCLUSIONS: SEMSs for MCO has high technical but suboptimal clinical success. Curved strictures and extrinsic compression are associated with poor outcomes. The perforation rate was not higher in the bevacizumab compared with the nonbevacizumab group, although this should be further validated in a larger population.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Lee JH, Emelogu I, Kukreja K, et al. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. Gastrointest Endosc. 2019. PMID: 30797835. doi:10.1016/j.gie.2019.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。